Alexion Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 100 Posts
1 2 3 ... 7
How Will Biotech ETFs React To These Q4 Earnings Releases?
Article By: Zacks Investment Research Saturday, February 6, 2021 4:47 PM EDT
Any positive news highlighting the progress of vaccine or antibody manufacturers is expected to create great returns for investors. Let’s take a look at some biotechnological earnings releases to see if these will impact ETFs exposed to the space.
In this article: BBH, IBB, XBI, BIIB, ALXN, GILD, AMGN
Read
AstraZeneca To Buy Rare-Disease Specialist Drugmaker Alexion For $39 Billion
Article By: Benzinga Saturday, December 12, 2020 12:07 PM EDT
AstraZeneca plc has announced it will buy Alexion Pharmaceuticals, Inc. for $39 billion. AstraZeneca and Alexion said this morning that their boards unanimously approved the deal. It is expected to close in the third quarter of 2021.
In this article: AZN, ALXN Also: PFE, BNTX
Read
3 BioTech Stocks To Buy On The Dip
Article By: StockNews Tuesday, November 17, 2020 10:37 AM EDT
Pfizer, Inc. and BioNTech SE’s vaccine news has created significant pressure on other biotech companies to launch their covid-19 vaccines or therapies soon.
In this article: ALXN, RARE, BNTX
Read
Alexion Pharmaceuticals: Growth At A Reasonable Price (GARP)
Article By: Chuck Carnevale Friday, July 10, 2020 2:02 PM EDT
It very interesting that Alexion Pharmaceuticals Inc. after going public in 2001, did not generate their first profit until December 2008. As we all know, this was in the throes of what is now known as the Great Recession of 2008.
In this article: ALXN
Read
Are Biotech ETFs In Trouble As Coronavirus Dims Guidance?
Article By: Zacks Investment Research Saturday, May 9, 2020 7:49 PM EDT
Although the coronavirus seems to be opening up opportunities for biotech companies, it is dampening their guidance as well. Despite impressive results, most of these biotechs have been seeing declining share prices since the earnings releases.
In this article: ALXN, IBB, AMGN, BIIB, GILD, BBH, XBI
Read
Biotech M&A Deal Looks Too Rich For Its Blood
Article By: Lipper Alpha Insight Wednesday, May 6, 2020 10:46 AM EDT
Alexion Pharmaceuticals (ALXN) is either buying Portola Pharmaceuticals (PTLA) on the cheap at $1.4 billion, or paying a whopping premium – it all depends on your starting date.
In this article: ALXN, PTLA
Read
5 Big Drug/Biotech Stocks Set To Trump Q4 Earnings Estimates
Article By: Zacks Investment Research Wednesday, January 22, 2020 4:00 PM EDT
A highlight of five big drug/biotech companies, which are expected to deliver positive earnings surprise in their upcoming quarterly earnings announcements.
In this article: AZN, MRK, ALXN, AMGN, ABBV
Read
Alexion To Acquire Achillion Pharma For $930M
Article By: Benzinga Wednesday, October 16, 2019 9:06 AM EDT
Alexion Pharma will buy Achillion Pharma for the initial value of $930 million, or $6.30 per share in cash plus added contingent considerations for a total potential value of $8.30 per share.
In this article: ALXN, ACHN
Read
3 Big Drug/Biotech Stocks Set To Beat Q3 Earnings Estimates
Article By: Zacks Investment Research Saturday, October 12, 2019 10:00 AM EDT
Overall, relatively newer drugs have been driving the top line of most of the big shots backed by higher demand - a trend we expect to have benefited third-quarter sales.
In this article: LLY, ALXN, AMGN Also: JNJ
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
A Glass Half Full Or Glass Half Empty – The Fate Of The Stock Market
Article By: Michael J. Kramer Tuesday, September 3, 2019 4:42 PM EDT
The three-ring circus continues with the S&P 500 on September 3 refilling a gap from last week.
In this article: GE, ALXN, AMZN, MSFT, SPX, SQ
Read
Healthcare And Biotechs Feel The Heat As The Market At New Highs
Article By: Tarun Chandra, CFA Wednesday, May 1, 2019 12:14 PM EDT
The stock market has continued to edge higher and the two major indexes, the Nasdaq (QQQ) and S&P 500 (SPY​), touched the all-time high milestone last week.
In this article: ACAD, ALXN, ARRY, AMRN, ARWR, AXSM, ASND
Read
5 Rallying Stocks For A Strong Q4
Article By: TipRanks Thursday, October 4, 2018 12:14 PM EDT
All these stocks are up over 10% or more in the last month.
In this article: CXO, CI, ALXN, BA, NTES
Read
Biotech ETFs In Focus On String Of Q2 Earnings Beats
Article By: Zacks Investment Research Sunday, August 12, 2018 4:27 PM EDT
The biotech sector has been performing remarkably well driven by a wave of mergers and acquisitions, new tax legislation, and a positive regulatory backdrop. Strong Q2 earnings results have added to the strength as biotech giants topped estimates.
In this article: IBB, AMGN, GILD, BBH, FBT, ALXN, BIIB
Read
Scan And Plan For Today’s Range And The Future Breakout
Video By: TheoTrade Thursday, May 24, 2018 5:01 PM EDT
Stocks sold off this morning on the news that President Trump canceled the meeting with North Korea. However, stocks recouped most of the loses by the close. In tonight's video newsletter we look at stocks that are break out candidates.
In this video: ALXN, USB, AMT, COO, DGX, HRB, CMG, PM
Watch
2018 Biotech Sector Watch On Earnings: ABBV, ALXN, BMY
Article By: Rod Raynovich Thursday, April 26, 2018 6:00 PM EDT
Abbvie (ABBV) is back on track. Alexion (ALXN) stock soared 14.6%. Bristol Myers-Squibb (BMY) raised its full year earnings forecast.
In this article: BMY, ALXN, ABBV Also: IBB, CELG, XBI, EDIT, CRSP
Read
1 to 16 of 100 Posts
1 2 3 ... 7